SKIP000600 |
SKIP ID |
SKIP000600 |
Organism(En) |
- |
Organism(Ja) |
- |
Cell Type(En) |
- |
Cell Type(Ja) |
- |
Cell Tissue(En) |
- |
Cell Tissue(Ja) |
- |
Cell Origin |
Diseased |
Cell Name 1(En) |
PDC3F-1 |
Cell Name 1(Ja) |
PDC3F-1 |
Cell Name 2(En) |
- |
Cell Name 2(Ja) |
- |
Disease Name 1(Ja) |
パーキンソン病 |
ICD Code 1 |
G20 |
Disease Name 1(En) |
Parkinson disease |
OMIM1 |
168600 |
Disease Name 2(Ja) |
- |
ICD Code 2 |
- |
Disease Name 2(En) |
- |
OMIM 2 |
- |
Disease Name 3(Ja) |
- |
ICD Code 3 |
- |
Disease Name 3(En) |
- |
OMIM 3 |
- |
Age |
57 |
Age Range |
50-59 |
Sex |
Male |
Race(En) |
- |
Race(Ja) |
- |
Genetic Diagnosis |
Yes |
Not Detected |
No |
Description(En) |
Human iPSCs were established via a constitutively active lentivirus expressing the reverse tetracycline transactivator (FUW-M2rtTA) together with DOX-inducible lentiviruses transducing three (OCT4, SOX2, KLF4) reprogramming factors into AG20446 fibroblasts. |
Description(Ja) |
皮膚線維芽細胞(AG20446)にリバーステトラサイクリントランスアクチベーター(FUW-M2rtTA)とDOX誘導型3因子(SOX2, OCT4, KLF4)をのせたレンチウイルスベクターを用いて樹立したヒト人工多能性幹細胞 (iPSC) 株。 |
Cell Morphology |
human ES-like |
Grade |
Research Grade |
Vector |
Lentivirus |
Transgene |
FUW-tetO 3 factors (OCT4, SOX2, KLF4) |
Adhesiveness |
- |
Feeder |
Yes |
Feeder Cell |
mitomycin C (MMC)-inactivated mouse embryonic fibroblast (MEF) feeder layers |
Medium |
hESC medium (DMEM/F12 [Invitrogen] supplemented with 15% FBS [Hyclone], 5% KnockOut Serum Replacement [Invitrogen], 1 mM glutamine [Invitrogen], 1% nonessential amino acids [Invitrogen], 0.1 mM β-mercaptoethanol [Sigma], and 4 ng/ml FGF2 [R&D Systems]) |
Genome Editing |
- |
CO2 |
- |
Mycoplasma |
- |
Detection of Contaminants Mycoplasma |
- |
Pluripotent Markers |
Yes |
Pluripotent Markers Assay |
- |
in vitro Differentiation |
Yes |
in vitro Differentiation Assay |
- |
in vivo Differentiation |
Yes |
in vivo Differentiation Assay |
teratoma formation |
Other 1 Assay |
- |
Other 1 Assay Method |
- |
Other 2 Assay |
- |
Other 2 Assay Method |
- |
Other 3 Assay |
- |
Other 3 Assay Method |
- |
Karyotype |
Yes |
Karyotype Assay |
- |
Remaining Vector Detection |
Yes |
Remaining Vector Detection Assay |
- |
STR |
- |
HLA |
- |
Stem Cell Transcriptome analysis |
Yes |
Stem Cell Transcriptome analysis Assay |
Microarray Gene Expression Analysis |
Author Name(En) |
Rudolf Jaenisch |
Author Name(Ja) |
Rudolf Jaenisch |
Author Organization(En) |
The Whitehead Institute |
Author Organization(Ja) |
The Whitehead Institute |
Author Contact Email |
- |
PI Organization(En) |
The Whitehead Institute |
PI Organization(Ja) |
The Whitehead Institute |
PI Name(En) |
Rudolf Jaenisch |
PI Name(Ja) |
Rudolf Jaenisch |
PI Contact Email |
- |
Availability |
Available |
Provider Organization(En) |
The Whitehead Institute |
Provider Organization(Ja) |
The Whitehead Institute |
Provider Email |
jaenisch[at]wi[dot]mit[dot]edu |
Provider URL |
- |
Ethical Statement(En) |
- |
Ethical Statement(Ja) |
- |
Terms of Use(En) |
- |
Terms of Use(Ja) |
- |
PubMed ID |
19269371 |
DOI |
10.1016/j.cell.2009.02.013 |
Title |
Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. |
Authors |
Soldner F, Hockemeyer D, Beard C, Gao Q, Bell GW, Cook EG, Hargus G, Blak A, Cooper O, Mitalipova M, Isacson O, Jaenisch R |
Journal |
Cell |
Year |
2009 |
Volume |
136 |
Issue |
5 |
Pages |
964-77 |
URL |
http://www.ncbi.nlm.nih.gov/pubmed/19269371 |
Free input |
- |
Note |
- |